Transcutaneous Versus Intraoral Photobiomodulation for the Prevention of Oral Mucositis in Head and Neck Cancer: A Randomized Clinical Trial
Objectives To compare the clinical efficacy of transcutaneous (TC-PBM) versus intraoral (IO-PBM) photobiomodulation in the prevention of radiotherapy-induced oral mucositis (OM) in patients with head and neck cancer. Methods This was a prospective, randomized, non-inferiority clinical trial involving 72 patients undergoing radiotherapy (RT) (60–70 Gy) for head and neck cancer (HNC), allocated to TC-PBM (n = 38), treated with an 808-nm laser using the following parameters: 100 mW, 1 J/point, 10 seconds per point, and 32 points, resulting in a fluence of 34.5 J/cm² (central) and 4.3 J/cm² (lateral); or IO-PBM (n = 34), treated with a 660-nm laser using the following parameters: 100 mW, 1 J/point, 10 seconds per point, and 44 points, resulting in a fluence of 10.20 J/cm². Treatments were applied three times weekly throughout the entire course of radiotherapy, from the first to the last day of RT. The primary outcome was OM severity (WHO scale, 0–4), and secondary outcomes included OM severity (NCI-CTC v2.0), pain (NRS), cumulative incidence, and time to OM onset, all assessed at T1 (1st week of RT), T2 (2nd week of RT), T3 (3rd week of RT), T4 (4th week of RT), and T5 (final week of RT). Results No significant difference was found in overall OM severity between groups (p = 0.549) or in the group × time interaction (p = 0.794). Estimated marginal means for OM grade were 1.88 (95% CI: 1.48–2.29) for the TC-PBM group and 2.18 (95% CI: 1.74–2.62) for the IO-PBM group, with an estimated between-group difference of − 0.30 (95% CI: −0.90 to 0.30), demonstrating the non-inferiority of TC-PBM. No significant differences were observed in cumulative OM incidence (71.1% in the TC-PBM group vs. 70.6% in the IO-PBM group; p = 0.965), median time to lesion onset (13 sessions in both groups; p = 0.436), pain intensity, or topographic distribution of lesions. Conclusion TC-PBM (808 nm) demonstrated non-inferiority to IO-PBM (660 nm) with respect to radiation-induced OM severity, while maintaining pain control. It represents a non-invasive strategy with a potential operational advantage (shorter application time), particularly relevant for patients with limited mouth opening, odynophagia, or compromised intraoral access.
Authors
- Luciana Almeida Lopes (ORCID: https://orcid.org/0000-0002-5873-2656)
- Waleska Tychanowicz Kolodziejwski (ORCID: https://orcid.org/0000-0001-6301-8767)
- Laurindo Moacir Sassi
- Giovanna Leal Klein Renz
- Isabela Busnello de Souza (ORCID: https://orcid.org/0009-0003-7486-5242)
- Maria Luisa Franceschi Coimbra
- Melissa Rodrigues de Araujo
Institutions
- Universidade Federal de Minas Gerais (BR)
- Hospital Erasto Gaertner (BR)
- Universidade Federal do Paraná (BR)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11272475/v1
- Primary Topic
- Oral health in cancer treatment
- Type
- preprint